(Q39475750)

English

Bortezomib represses HIF-1α protein expression and nuclear accumulation by inhibiting both PI3K/Akt/TOR and MAPK pathways in prostate cancer cells

scientific article published on 10 September 2011

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

Bortezomib represses HIF-1α protein expression and nuclear accumulation by inhibiting both PI3K/Akt/TOR and MAPK pathways in prostate cancer cells (English)

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

prostate cancer

1 reference

based on heuristic

inferred from title

corrigendum / erratum

Erratum to: Bortezomib represses HIF-1α protein expression and nuclear accumulation by inhibiting both PI3K/Akt/TOR and MAPK pathways in prostate cancer cells.

0 references

Panagiotis Liakos

object named as

Panagiotis Liakos

8

0 references

object named as

George Simos

6

0 references

author name string

Christina D Befani

1

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

Panagiotis J Vlachostergios

2

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

Eleana Hatzidaki

3

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

Anna Patrikidou

4

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

Sophia Bonanou

5

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

Christos N Papandreou

7

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

language of work or name

1 reference

based on heuristic

inferred from title

publication date

10 September 2011

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

Journal of Molecular Medicine

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

90

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

1

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

45-54

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

Development of the proteasome inhibitor Velcade (Bortezomib).

1 reference

https://api.crossref.org/works/10.1007%2FS00109-011-0805-8

21 January 2018

Bortezomib as a potential treatment for prostate cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00109-011-0805-8

21 January 2018

Bortezomib mediates antiangiogenesis in multiple myeloma via direct and indirect effects on endothelial cells

1 reference

https://api.crossref.org/works/10.1007%2FS00109-011-0805-8

21 January 2018

Regulation of cancer cell metabolism by hypoxia-inducible factor 1.

1 reference

https://api.crossref.org/works/10.1007%2FS00109-011-0805-8

21 January 2018

PI3K/PTEN signaling in angiogenesis and tumorigenesis

1 reference

https://api.crossref.org/works/10.1007%2FS00109-011-0805-8

21 January 2018

MAPK signaling up-regulates the activity of hypoxia-inducible factors by its effects on p300

1 reference

https://api.crossref.org/works/10.1007%2FS00109-011-0805-8

21 January 2018

p42/p44 mitogen-activated protein kinases phosphorylate hypoxia-inducible factor 1alpha (HIF-1alpha) and enhance the transcriptional activity of HIF-1.

1 reference

https://api.crossref.org/works/10.1007%2FS00109-011-0805-8

21 January 2018

Identification of MAPK phosphorylation sites and their role in the localization and activity of hypoxia-inducible factor-1alpha.

1 reference

https://api.crossref.org/works/10.1007%2FS00109-011-0805-8

21 January 2018

Atypical CRM1-dependent nuclear export signal mediates regulation of hypoxia-inducible factor-1alpha by MAPK.

1 reference

https://api.crossref.org/works/10.1007%2FS00109-011-0805-8

21 January 2018

Flavonoids induce HIF-1alpha but impair its nuclear accumulation and activity

1 reference

https://api.crossref.org/works/10.1007%2FS00109-011-0805-8

21 January 2018

Bortezomib inhibits tumor adaptation to hypoxia by stimulating the FIH-mediated repression of hypoxia-inducible factor-1.

1 reference

https://api.crossref.org/works/10.1007%2FS00109-011-0805-8

21 January 2018

Proteasomal inhibition attenuates transcriptional activity of hypoxia-inducible factor 1 (HIF-1) via specific effect on the HIF-1alpha C-terminal activation domain

1 reference

https://api.crossref.org/works/10.1007%2FS00109-011-0805-8

21 January 2018

Suppression of the hypoxia-inducible factor-1 response in cervical carcinoma xenografts by proteasome inhibitors

1 reference

https://api.crossref.org/works/10.1007%2FS00109-011-0805-8

21 January 2018

Control of HIF-1alpha expression by eIF2 alpha phosphorylation-mediated translational repression

1 reference

https://api.crossref.org/works/10.1007%2FS00109-011-0805-8

21 January 2018

Inverse baseline expression pattern of the NEP/neuropeptides and NFκB/proteasome pathways in androgen-dependent and androgen-independent prostate cancer cells

1 reference

https://api.crossref.org/works/10.1007%2FS00109-011-0805-8

21 January 2018

Proteasome inhibitor PS-341 down-regulates prostate-specific antigen (PSA) and induces growth arrest and apoptosis of androgen-dependent human prostate cancer LNCaP cells

1 reference

https://api.crossref.org/works/10.1007%2FS00109-011-0805-8

21 January 2018

Targeting BCL-2 overexpression in various human malignancies through NF-kappaB inhibition by the proteasome inhibitor bortezomib

1 reference

https://api.crossref.org/works/10.1007%2FS00109-011-0805-8

21 January 2018

Hypoxia-inducible factor-1 in human breast and prostate cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00109-011-0805-8

21 January 2018

Androgens regulate the binding of endogenous HuR to the AU-rich 3'UTRs of HIF-1alpha and EGF mRNA.

1 reference

https://api.crossref.org/works/10.1007%2FS00109-011-0805-8

21 January 2018

Hypoxia enhances transcriptional activity of androgen receptor through hypoxia-inducible factor-1α in a low androgen environment

1 reference

https://api.crossref.org/works/10.1007%2FS00109-011-0805-8

21 January 2018

The power and promise of "rewiring" the mitogen-activated protein kinase network in prostate cancer therapeutics

1 reference

https://api.crossref.org/works/10.1007%2FS00109-011-0805-8

21 January 2018

Down-regulation of phospho-Akt is a major molecular determinant of bortezomib-induced apoptosis in hepatocellular carcinoma cells

1 reference

https://api.crossref.org/works/10.1007%2FS00109-011-0805-8

21 January 2018

Differential cellular and molecular effects of bortezomib, a proteasome inhibitor, in human breast cancer cells

1 reference

https://api.crossref.org/works/10.1007%2FS00109-011-0805-8

21 January 2018

Bortezomib is an efficient agent in plasma cell leukemias

1 reference

https://api.crossref.org/works/10.1007%2FS00109-011-0805-8

21 January 2018

Proteasome inhibitor PS-341 abrogates IL-6 triggered signaling cascades via caspase-dependent downregulation of gp130 in multiple myeloma

1 reference

https://api.crossref.org/works/10.1007%2FS00109-011-0805-8

21 January 2018

The dietary flavonoid kaempferol effectively inhibits HIF-1 activity and hepatoma cancer cell viability under hypoxic conditions

1 reference

https://api.crossref.org/works/10.1007%2FS00109-011-0805-8

21 January 2018

Up-regulation of hypoxia-inducible factor 1alpha is an early event in prostate carcinogenesis.

1 reference

https://api.crossref.org/works/10.1007%2FS00109-011-0805-8

21 January 2018

The androgen receptor is significantly associated with vascular endothelial growth factor and hypoxia sensing via hypoxia-inducible factors HIF-1a, HIF-2a, and the prolyl hydroxylases in human prostate cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00109-011-0805-8

21 January 2018

Transformation of mammalian cells by constitutively active MAP kinase kinase

1 reference

https://pubmed.ncbi.nlm.nih.gov/21909688

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Mitogen-activated protein kinase kinase inhibitor PD98059 blocks the trans-activation but not the stabilization or DNA binding ability of hypoxia-inducible factor-1alpha

1 reference

https://pubmed.ncbi.nlm.nih.gov/21909688

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Hypoxia-inducible transcription factor-1 alpha determines sensitivity of endothelial cells to the proteosome inhibitor bortezomib

1 reference

https://pubmed.ncbi.nlm.nih.gov/21909688

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Hyperinducibility of hypoxia-responsive genes without p53/p21-dependent checkpoint in aggressive prostate cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/21909688

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Overexpression of hypoxia-inducible factor 1alpha in common human cancers and their metastases

1 reference

https://pubmed.ncbi.nlm.nih.gov/21909688

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Targeting AKT/mTOR and ERK MAPK signaling inhibits hormone-refractory prostate cancer in a preclinical mouse model

1 reference

https://pubmed.ncbi.nlm.nih.gov/21909688

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Androgens stimulate hypoxia-inducible factor 1 activation via autocrine loop of tyrosine kinase receptor/phosphatidylinositol 3'-kinase/protein kinase B in prostate cancer cells

1 reference

https://pubmed.ncbi.nlm.nih.gov/21909688

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S00109-011-0805-8

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q39475750&oldid=2202913408"